Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=1426
{ "count": 24348, "next": "http://api.gregory-ms.com/articles/?format=api&page=1427", "previous": "http://api.gregory-ms.com/articles/?format=api&page=1425", "results": [ { "article_id": 380650, "title": "A novel classification of fatigue in multiple sclerosis based on longitudinal assessments", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Magnetic resonance imaging (MRI) studies of multiple sclerosis–related fatigue had limited reproducibility. Temporal fatigue fluctuations have not been considered. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To investigate whether a novel group allocation that reflects temporal dynamics of fatigue improves our ability to detect fatigue-associated structural brain abnormalities. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> Patient stratification based on biennial fatigue assessments: sustained fatigue (SF, n = 29, fatigued at the latest ⩾2 assessments), one time-point fatigue (1F, n = 15, fatigued at the latest, but non-fatigued at the penultimate assessment), reversible fatigue (RF, n = 31, non-fatigued at the latest assessment, but reported fatigue previously), and never fatigued (NF, n = 54). Brain parenchymal fraction (BPF) and T2 lesion volume (T2LV) were compared between these groups and were derived using a conventional, single time-point fatigued versus non-fatigued stratification. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> The SF versus NF stratification yielded improved power. SF ( p = 0.005) and RF ( p = 0.043) showed significantly higher T2LV than NF. T2LV showed no significant differences in SF versus 1F, SF versus RF, or 1F versus RF. Fatigued versus non-fatigued patients showed significantly higher T2LV ( p = 0.030). We found no significant differences in BPF between the groups. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Taking into account temporal fatigue dynamics increases the statistical power with respect to T2LV and may improve characterization of brain pathological correlates of MS-related fatigue. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458519898112", "published_date": "2020-01-23T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 150413, "given_name": "Miklos", "family_name": "Palotai", "ORCID": "http://orcid.org/0000-0003-0268-6977", "country": null }, { "author_id": 250573, "given_name": "Michele", "family_name": "Cavallari", "ORCID": null, "country": null }, { "author_id": 173285, "given_name": "Brian C", "family_name": "Healy", "ORCID": "http://orcid.org/0000-0001-5272-2425", "country": null }, { "author_id": 250579, "given_name": "Charles RG", "family_name": "Guttmann", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "A novel classification", "fatigue", "multiple sclerosis", "longitudinal assessments" ], "doi": "10.1177/1352458519898112", "access": "restricted", "takeaways": " Magnetic resonance imaging studies of MS-related fatigue had limited reproducibility . Temporal fatigue fluctuations have not been considered . Taking into account temporal fatigue dynamics increases the statistical power with respect to T2LV .", "categories": [] }, { "article_id": 381667, "title": "Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning", "summary": "<jats:p> We report on a so-far never described association between glomerulonephritis and sarcoid-like lung disease after long-term interferon beta (IFNb) treatment for relapsing–remitting multiple sclerosis. The interest in this case resides in the documented remission after IFNb discontinuation. The history of IFNb-related adverse events is probably not yet completely written. The rapid reversal of the pathological signs in our patient underlines the importance of careful clinical and laboratory surveillance, including kidney functional parameters, for an early diagnosis of IFNb-related diseases. </jats:p>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458513519180", "published_date": "2014-01-20T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 148579, "given_name": "Marco", "family_name": "Capobianco", "ORCID": "http://orcid.org/0000-0003-2501-2932", "country": null }, { "author_id": 309563, "given_name": "Giorgina", "family_name": "Piccoli", "ORCID": null, "country": null }, { "author_id": 309564, "given_name": "Federica", "family_name": "Neve Vigotti", "ORCID": null, "country": null }, { "author_id": 309565, "given_name": "Paola", "family_name": "Scapoli", "ORCID": null, "country": null }, { "author_id": 309566, "given_name": "Maria Chiara", "family_name": "Deagostini", "ORCID": null, "country": null }, { "author_id": 309567, "given_name": "Carlo", "family_name": "Albera", "ORCID": null, "country": null }, { "author_id": 309568, "given_name": "Dario", "family_name": "Roccatello", "ORCID": null, "country": null }, { "author_id": 166047, "given_name": "Antonio", "family_name": "Bertolotto", "ORCID": "http://orcid.org/0000-0002-7052-1907", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Interferon beta-related nephropathy and interstitial lung disease", "a new association", "a long-term warning" ], "doi": "10.1177/1352458513519839", "access": "open", "takeaways": " We report on a so-far never described association between glomerulonephritis and sarcoid-like lung disease after long-term interferon beta (IFN", "categories": [] }, { "article_id": 380850, "title": "Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Recent basic and clinical evidence suggests amiloride may be neuroprotective in multiple sclerosis (MS) through the blockade of the acid sensing ion channel (ASIC). </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To examine the neuroprotective efficacy of amiloride in acute optic neuritis (ON). </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> A total of 48 patients were recruited to a phase 2, double blind, single site, randomised controlled trial. Scanning laser polarimetry (GDx) at 6 months was the primary outcome measure and optical coherence tomography (OCT) and visual and electrophysiological measures were secondary outcome measures. Participants aged 18–55 years, ≤28 days of onset of first episode unilateral ON, were randomised to amiloride (10 mg daily for 5 months) or placebo ( clinicaltrials.gov , NCT 01802489). </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Intention-to-treat (ITT) cohort consisted of 43 patients; 23 placebo and 20 amiloride. No significant drug-related adverse events occurred. No significant differences were found in GDx ( p = 0.840). Visual evoked potentials (VEP) were significantly prolonged in the amiloride group compared to placebo ( p = 0.004). All other secondary outcome measures showed no significant difference. Baseline analysis of OCT data demonstrated a significant pre-randomisation thinning of ganglion cell layer. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Amiloride has not demonstrated any neuroprotective benefit within this trial paradigm, but future neuroprotective trials in ON should target the window of opportunity to maximise potential neuroprotective benefit. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458517742979", "published_date": "2017-11-27T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 268154, "given_name": "Justin B", "family_name": "McKee", "ORCID": null, "country": null }, { "author_id": 268155, "given_name": "Charles L", "family_name": "Cottriall", "ORCID": null, "country": null }, { "author_id": 268156, "given_name": "John", "family_name": "Elston", "ORCID": null, "country": null }, { "author_id": 268157, "given_name": "Simon", "family_name": "Epps", "ORCID": null, "country": null }, { "author_id": 148608, "given_name": "Nikos", "family_name": "Evangelou", "ORCID": "http://orcid.org/0000-0003-2871-0672", "country": null }, { "author_id": 268158, "given_name": "Stephen", "family_name": "Gerry", "ORCID": null, "country": null }, { "author_id": 268159, "given_name": "Christopher", "family_name": "Kennard", "ORCID": null, "country": null }, { "author_id": 213929, "given_name": "Yazhuo", "family_name": "Kong", "ORCID": "http://orcid.org/0000-0002-8249-4723", "country": null }, { "author_id": 268160, "given_name": "Abigail", "family_name": "Koelewyn", "ORCID": null, "country": null }, { "author_id": 268162, "given_name": "Wilhelm", "family_name": "Kueker", "ORCID": null, "country": null }, { "author_id": 255523, "given_name": "Maria Isabel", "family_name": "Leite", "ORCID": null, "country": null }, { "author_id": 245422, "given_name": "Jacqueline", "family_name": "Palace", "ORCID": null, "country": null }, { "author_id": 268165, "given_name": "Matthew", "family_name": "Craner", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Amiloride", "retinal nerve fibre layer thickness", "optic neuritis", "a phase", "2 randomised controlled trial" ], "doi": "10.1177/1352458517742979", "access": "open", "takeaways": " 48 patients were recruited to a phase 2, double blind, single site, randomised controlled trial . No significant drug-related adverse events occurred . Amiloride has not demonstrated any neuroprotective benefit within this trial paradigm .", "categories": [] }, { "article_id": 380549, "title": "Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosis", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Persons with multiple sclerosis (MS) commonly report word-finding difficulty clinically, yet this language deficit remains underexplored. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To investigate the prevalence and nature of word-finding difficulty in persons with early MS on three levels: patient report, cognitive substrates, and neuroimaging. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> Two samples of early MS patients ( n = 185 and n = 55; ⩽5 years diagnosed) and healthy controls ( n = 50) reported frequency/severity of cognitive deficits and underwent objective assessment with tasks of rapid automatized naming (RAN), measuring lexical access speed, memory, word generation, and cognitive efficiency. High-resolution brain magnetic resonance imaging (MRI) derived measurements of regional cortical thickness, global and deep gray matter volume, and T2 lesion volume. Relationships among patient-reported word-finding difficulty, cognitive performance, and neural correlates were examined. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Word-finding difficulty was the most common cognitive complaint of MS patients and the only complaint reported more by patients than healthy controls. Only RAN performance discriminated MS patients with subjective word-finding deficits from those without subjective complaints and from healthy controls. Thinner left parietal cortical gray matter independently predicted impaired RAN performance, driven primarily by the left precuneus. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Three levels of evidence (patient-report, objective behavior, regional gray matter) support word-finding difficulty as a prevalent, measurable, disease-related deficit in early MS linked to left parietal cortical thinning. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458519881760", "published_date": "2019-11-19T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 248997, "given_name": "Rachel", "family_name": "Brandstadter", "ORCID": null, "country": null }, { "author_id": 253789, "given_name": "Michelle", "family_name": "Fabian", "ORCID": null, "country": null }, { "author_id": 253094, "given_name": "Victoria M", "family_name": "Leavitt", "ORCID": null, "country": null }, { "author_id": 240958, "given_name": "Stephen", "family_name": "Krieger", "ORCID": null, "country": null }, { "author_id": 256271, "given_name": "Anusha", "family_name": "Yeshokumar", "ORCID": null, "country": null }, { "author_id": 174425, "given_name": "Ilana", "family_name": "Katz Sand", "ORCID": "http://orcid.org/0000-0001-5107-4761", "country": null }, { "author_id": 165746, "given_name": "Sylvia", "family_name": "Klineova", "ORCID": "http://orcid.org/0000-0002-0406-0460", "country": null }, { "author_id": 256272, "given_name": "Claire S", "family_name": "Riley", "ORCID": null, "country": null }, { "author_id": 256273, "given_name": "Christina", "family_name": "Lewis", "ORCID": null, "country": null }, { "author_id": 256274, "given_name": "Gabrielle", "family_name": "Pelle", "ORCID": null, "country": null }, { "author_id": 172546, "given_name": "Fred D", "family_name": "Lublin", "ORCID": "http://orcid.org/0000-0001-5722-0475", "country": null }, { "author_id": 179887, "given_name": "Aaron E", "family_name": "Miller", "ORCID": "http://orcid.org/0000-0001-8324-7356", "country": null }, { "author_id": 165751, "given_name": "James F", "family_name": "Sumowski", "ORCID": "http://orcid.org/0000-0001-6111-4907", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Word-finding difficulty", "a prevalent disease-related deficit", "early multiple sclerosis" ], "doi": "10.1177/1352458519881760", "access": "open", "takeaways": " Word-finding difficulty was the most common cognitive complaint of MS patients and the only complaint reported more by patients than healthy controls . Thinner left parietal cortical cortical gray matter independently predicted impaired word-finding deficits .", "categories": [] }, { "article_id": 380520, "title": "New applications for independent activities of daily living in measuring disability in multiple sclerosis", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Disability outcome measures in multiple sclerosis (MS) focus heavily on ambulation; however, limitations in performing everyday activities encompass another type of disability. </jats:p></jats:sec><jats:sec><jats:title>Objectives:</jats:title><jats:p> The aim of this study was to examine the ability of instrumental activities of daily living (IADL) scale to discriminate between different levels of disability and to predict disability progression. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> The North American Research Committee on Multiple Sclerosis (NARCOMS) registry fall 2006 semi-annual survey asked participants to complete the RAND-12, Performance Scales, Patient Determined Disease Steps (PDDS), and IADL questionnaires. We modeled the trajectory of disability change, using the PDDS, over 12 years. Analyses used linear and repeated measures regression methods. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Of respondents ( n = 9931), 9559 (96%) completed the PDDS and IADL scale. Respondents were mostly female (76%), Caucasian (92%), and 52.3 (10.5) years old with moderate disability (median PDDS 4 (early cane)). Mean (SD) IADL total score was 20.5 (3.7). Discriminant ability of the IADL scale was higher than other measures considered at higher levels of disability. Adjusted longitudinal models showed that needing greater assistance on IADLs was independently predictive of trajectories of greater disability change. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> IADL scale had a greater ability to discriminate between higher disability levels than RAND-12 domains. The IADL scale may provide a useful and clinically relevant tool to measure disability in progressive MS populations. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458519898591", "published_date": "2020-01-14T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 147498, "given_name": "Amber", "family_name": "Salter", "ORCID": "http://orcid.org/0000-0002-1088-110X", "country": "US" }, { "author_id": 143705, "given_name": "Robert J", "family_name": "Fox", "ORCID": "http://orcid.org/0000-0002-4263-3717", "country": "US" }, { "author_id": 205363, "given_name": "Tuula", "family_name": "Tyry", "ORCID": "http://orcid.org/0000-0002-9282-3455", "country": null }, { "author_id": 240824, "given_name": "Gary", "family_name": "Cutter", "ORCID": null, "country": null }, { "author_id": 159118, "given_name": "Ruth Ann", "family_name": "Marrie", "ORCID": "http://orcid.org/0000-0002-1855-5595", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "New applications", "independent activities", "disability", "multiple sclerosis" ], "doi": "10.1177/1352458519898591", "access": "restricted", "takeaways": " Disability outcome measures in multiple sclerosis focus heavily on ambulation . But limitations in performing everyday activities encompass another type of disability . IADL scale may provide a useful tool to measure disability in progressive MS populations .", "categories": [] }, { "article_id": 381385, "title": "Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Mobility impairment is a common disability in MS and negatively impacts patients’ lives. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> Evaluate the effect of prolonged-release (PR) fampridine (extended-release dalfampridine in the United States) on self-assessed walking disability, dynamic/static balance and safety in patients with MS. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> MOBILE was a randomised, double-blind, exploratory, placebo-controlled trial. Patients with progressive/relapsing-remitting MS and Expanded Disability Status Scale score of 4.0–7.0 were treated with PR-fampridine or placebo twice daily for 24 weeks. Efficacy endpoints included change from baseline in the 12-item MS Walking Scale (MSWS-12), Timed Up and Go (TUG) test and Berg Balance Scale (BBS). </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> 132 patients were randomised at 24 sites in six countries. PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, TUG speed and BBS total score versus placebo over 24 weeks. A higher proportion of patients receiving PR-fampridine versus placebo experienced significant improvements at MSWS-12 improvement thresholds ⩾7 ( p = 0.0275), ⩾8 ( p = 0.0153) and ⩾9 points ( p = 0.0088) and TUG speed thresholds ⩾10% ( p = 0.0021) and ⩾15% ( p = 0.0262). PR-fampridine was well tolerated. </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> PR-fampridine therapy resulted in early and sustained improvements in broad measures of walking and balance over six months. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458515581436", "published_date": "2015-04-28T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 180862, "given_name": "Raymond", "family_name": "Hupperts", "ORCID": "http://orcid.org/0000-0003-2106-2158", "country": null }, { "author_id": 173692, "given_name": "Jan", "family_name": "Lycke", "ORCID": "http://orcid.org/0000-0002-7891-8466", "country": null }, { "author_id": 256150, "given_name": "Christine", "family_name": "Short", "ORCID": null, "country": null }, { "author_id": 169915, "given_name": "Claudio", "family_name": "Gasperini", "ORCID": "http://orcid.org/0000-0002-3959-4067", "country": null }, { "author_id": 256151, "given_name": "Manjit", "family_name": "McNeill", "ORCID": null, "country": null }, { "author_id": 250652, "given_name": "Rossella", "family_name": "Medori", "ORCID": null, "country": null }, { "author_id": 256152, "given_name": "Agata", "family_name": "Tofil-Kaluza", "ORCID": null, "country": null }, { "author_id": 256153, "given_name": "Maria", "family_name": "Hovenden", "ORCID": null, "country": null }, { "author_id": 256154, "given_name": "Lahar R", "family_name": "Mehta", "ORCID": null, "country": null }, { "author_id": 250654, "given_name": "Jacob", "family_name": "Elkins", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Prolonged-release fampridine", "walking", "balance", "MS", "randomised controlled MOBILE trial" ], "doi": "10.1177/1352458515581436", "access": "open", "takeaways": " MOBILE was a randomised, double-blind, exploratory, placebo-controlled trial . 132 patients were randomised at 24 sites in six countries . PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, TUG speed and BBS total score .", "categories": [] }, { "article_id": 380828, "title": "Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Younger age, male sex and presence of spinal cord lesion(s) increase the risk of conversion from radiologically isolated syndrome (RIS) to relapsing-remitting multiple sclerosis (RRMS). Elevated cerebrospinal fluid (CSF) chitinase-3-like protein 1 (CHI3L1) levels predict conversion from clinically isolated syndrome (CIS) to RRMS. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To evaluate the prognostic value of CSF CHI3L1 in RIS patients for conversion to RRMS. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> We compared CSF CHI3L1 concentrations in RIS, CIS, RRMS and symptomatic controls (SCs). We analysed the influence of epidemiological, radiological and CSF parameters on the risk of clinical event. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> A total of 211 patients (71 RIS, 48 CIS, 50 RRMS and 42 SC) were included. CSF CHI3L1 levels were lower in RIS than in RRMS and higher in RIS with positive CSF versus negative CSF and SC. The presence of at least one spinal cord lesion was the only independent predictor of faster conversion to RRMS. Association of high CSF CHI3L1 levels, positive CSF (presence of oligoclonal bands and/or an elevated IgG index) or four Barkhof criteria with any spinal cord lesion showed a tendency for reduced mean conversion time. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> CSF CHI3L1 correlates with positive CSF but is not an independent predictor of the risk of conversion from RIS to RRMS. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458518767043", "published_date": "2018-03-22T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 176046, "given_name": "Eric", "family_name": "Thouvenot", "ORCID": "http://orcid.org/0000-0001-8671-7747", "country": "FR" }, { "author_id": 262283, "given_name": "Geoffrey", "family_name": "Hinsinger", "ORCID": null, "country": null }, { "author_id": 262284, "given_name": "Christophe", "family_name": "Demattei", "ORCID": null, "country": null }, { "author_id": 262286, "given_name": "Ugur", "family_name": "Uygunoglu", "ORCID": null, "country": null }, { "author_id": 241148, "given_name": "Giovanni", "family_name": "Castelnovo", "ORCID": null, "country": null }, { "author_id": 247684, "given_name": "Sophie", "family_name": "Pittion-Vouyovitch", "ORCID": null, "country": null }, { "author_id": 262287, "given_name": "Darin", "family_name": "Okuda", "ORCID": null, "country": null }, { "author_id": 211428, "given_name": "Orhun", "family_name": "Kantarci", "ORCID": "http://orcid.org/0000-0001-7038-8133", "country": null }, { "author_id": 243482, "given_name": "Daniel", "family_name": "Pelletier", "ORCID": null, "country": null }, { "author_id": 262289, "given_name": "Philippe", "family_name": "Marin", "ORCID": null, "country": null }, { "author_id": 167433, "given_name": "Aksel", "family_name": "Siva", "ORCID": "http://orcid.org/0000-0002-8340-6641", "country": null }, { "author_id": 262290, "given_name": "Christine", "family_name": "Lebrun", "ORCID": null, "country": null }, { "author_id": 325826, "given_name": "Sylvain", "family_name": "Lehmann", "ORCID": "http://orcid.org/0000-0001-6117-562X", "country": "FR" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Cerebrospinal fluid chitinase-3-like protein 1 level", "an independent predictive factor", "the risk", "clinical conversion", "radiologically isolated syndrome" ], "doi": "10.1177/1352458518767043", "access": "restricted", "takeaways": " CSF chitinase-3-like protein 1 (CHI3L1) levels predict conversion from clinically isolated syndrome (CIS) to RRMS . Younger age, male sex and presence of spinal cord lesion(s) increase the risk of conversion .", "categories": [] }, { "article_id": 380925, "title": "Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> The current best practice suggests yearly magnetic resonance imaging (MRI) to monitor treatment response in multiple sclerosis (MS) patients. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To evaluate the current practice of clinicians changing MS treatment based on subclinical new MRI lesions alone. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> Using MSBase, an international MS patient registry with MRI data, we analysed the probability of treatment change among patients with clinically silent new MRI lesions. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> A total of 8311 MRI brain scans of 4232 patients were identified. Around 26.9% (336/1247) MRIs with one new T2 lesion were followed by disease-modifying therapy (DMT) change, increasing to 50.2% (129/257) with six new T2 lesions. DMT change was twice as likely with new T1 contrast enhancing compared to new T2 lesions odds ratio (OR): 2.43, 95% confidence interval (CI): 2.00–2.96 vs OR: 1.26 (95% CI: 1.22–1.29). DMT change with new MRI lesions occurred most frequently with ‘injectable’ DMTs. The probability of switching therapy was greater only after high-efficacy therapies became available in 2007 (after, OR: 1.43, 95% CI: 1.28–1.59 vs before, OR: 0.98, 95% CI: 0.520–1.88). </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> MS clinicians rely increasingly on MRI alone in their treatment decisions, utilizing low thresholds (1 new T2 lesion) for optimizing MS therapy. This signals a shift towards no evidence of disease activity (NEDA)-3 since high-efficacy therapies became available. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458518798147", "published_date": "2018-09-20T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 180639, "given_name": "Tim", "family_name": "Spelman", "ORCID": "http://orcid.org/0000-0001-9204-3216", "country": null }, { "author_id": 148215, "given_name": "Alessandra", "family_name": "Lugaresi", "ORCID": "http://orcid.org/0000-0003-2902-5589", "country": "IT" }, { "author_id": 151333, "given_name": "Cavit", "family_name": "Boz", "ORCID": "http://orcid.org/0000-0003-0956-3304", "country": null }, { "author_id": 260257, "given_name": "Daniele LA", "family_name": "Spitaleri", "ORCID": null, "country": null }, { "author_id": 260256, "given_name": "Eugenio", "family_name": "Pucci", "ORCID": null, "country": null }, { "author_id": 241020, "given_name": "Francois", "family_name": "Grand’Maison", "ORCID": null, "country": null }, { "author_id": 242442, "given_name": "Franco", "family_name": "Granella", "ORCID": null, "country": null }, { "author_id": 240611, "given_name": "Guillermo", "family_name": "Izquierdo", "ORCID": null, "country": null }, { "author_id": 171213, "given_name": "Helmut", "family_name": "Butzkueven", "ORCID": "http://orcid.org/0000-0003-3940-8727", "country": "AU" }, { "author_id": 260017, "given_name": "Jose Luis", "family_name": "Sanchez-Menoyo", "ORCID": null, "country": null }, { "author_id": 241029, "given_name": "Michael", "family_name": "Barnett", "ORCID": null, "country": null }, { "author_id": 182584, "given_name": "Marc", "family_name": "Girard", "ORCID": "http://orcid.org/0000-0001-8207-8896", "country": null }, { "author_id": 152739, "given_name": "Maria", "family_name": "Trojano", "ORCID": "http://orcid.org/0000-0002-6329-8946", "country": null }, { "author_id": 204671, "given_name": "Pierre", "family_name": "Grammond", "ORCID": "http://orcid.org/0000-0001-6341-724X", "country": "CA" }, { "author_id": 183403, "given_name": "Pierre", "family_name": "Duquette", "ORCID": "http://orcid.org/0000-0001-7231-1754", "country": null }, { "author_id": 148208, "given_name": "Patrizia", "family_name": "Sola", "ORCID": "http://orcid.org/0000-0002-1700-1726", "country": null }, { "author_id": 157717, "given_name": "Raed", "family_name": "Alroughani", "ORCID": "http://orcid.org/0000-0001-5436-5804", "country": null }, { "author_id": 180862, "given_name": "Raymond", "family_name": "Hupperts", "ORCID": "http://orcid.org/0000-0003-2106-2158", "country": null }, { "author_id": 160168, "given_name": "Steve", "family_name": "Vucic", "ORCID": "http://orcid.org/0000-0002-8323-873X", "country": null }, { "author_id": 160181, "given_name": "Tomas", "family_name": "Kalincik", "ORCID": "http://orcid.org/0000-0003-3778-1376", "country": null }, { "author_id": 297269, "given_name": "Vincent", "family_name": "Van pesch", "ORCID": null, "country": null }, { "author_id": 177180, "given_name": "Jeannette", "family_name": "Lechner-Scott", "ORCID": "http://orcid.org/0000-0002-3850-447X", "country": null }, { "author_id": 290769, "given_name": "Myintzu", "family_name": "Min", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Silent lesions", "MRI imaging", "goal posts", "treatment decisions", "multiple sclerosis" ], "doi": "10.1177/1352458518798147", "access": "restricted", "takeaways": " Current best practice suggests yearly magnetic resonance imaging (MRI) to monitor treatment response in multiple sclerosis patients . Around 26.9% of MRIs with one new T2 lesion were followed by disease-modifying therapy (DMT) change, increasing to 50.2% with six new lesions . DMT change with new MRI lesions occurred most frequently with ‘injectable’ DMTs .", "categories": [] }, { "article_id": 381469, "title": "A new risk variant for multiple sclerosis at the immunoglobulin heavy chain locus associates with intrathecal IgG, IgM index and oligoclonal bands", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Recent findings have shown a correlation between the intrathecal IgG index and variants at the immunoglobulin heavy chain (IGHC) locus in patients with multiple sclerosis (MS). </jats:p></jats:sec><jats:sec><jats:title>Objectives:</jats:title><jats:p> The objective of this paper is to analyse the association of the locus with MS susceptibility and its relationship with intrathecal immunoglobulin (Ig) parameters. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> We genotyped the rs11621145 variant, located at the IGHC locus, in 2726 patients with MS and 2133 healthy controls. Associations of intrathecal IgG and IgM indexes with rs11621145 were analysed by linear regression analysis in 538 MS patients. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> We found that rs11621145 showed statistically significant evidence for association with susceptibility to MS (odds ratio = 0.69, p = 1.053E-09), though validation of this result in additional cohorts would be desirable. We confirmed the association between the IgG index and the rs11621145 ( p = 6.85E-07, Beta = 0.207). Furthermore, rs11621145 was inversely correlated with IgM index ( p = 7.24E-04, Beta = -0.277), and therefore marks a decreased likelihood of presenting IgM oligoclonal bands (odds ratio = 0.38, p = 2.35E-06). </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> Our results suggest that the polymorphism of the IGHC locus could be altering the switching of the Ig isotype in B cells and it may be interfering with T-dependent and T-independent antibody responses. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458515603801", "published_date": "2014-11-12T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 253189, "given_name": "Mercedes", "family_name": "Delgado-García", "ORCID": null, "country": null }, { "author_id": 179685, "given_name": "Fuencisla", "family_name": "Matesanz", "ORCID": "http://orcid.org/0000-0002-9429-1819", "country": null }, { "author_id": 179677, "given_name": "Antonio", "family_name": "Alcina", "ORCID": "http://orcid.org/0000-0001-7294-0948", "country": null }, { "author_id": 242018, "given_name": "María", "family_name": "Fedetz", "ORCID": null, "country": null }, { "author_id": 253191, "given_name": "María Isabel", "family_name": "García-Sánchez", "ORCID": null, "country": null }, { "author_id": 249445, "given_name": "Juan Luis", "family_name": "Ruiz-Peña", "ORCID": null, "country": null }, { "author_id": 148768, "given_name": "Óscar", "family_name": "Fernández", "ORCID": "http://orcid.org/0000-0003-3696-789X", "country": "ES" }, { "author_id": 253192, "given_name": "María Jesús", "family_name": "Pinto Medel", "ORCID": null, "country": null }, { "author_id": 253193, "given_name": "Laura", "family_name": "Leyva", "ORCID": null, "country": null }, { "author_id": 253194, "given_name": "Carmen", "family_name": "Arnal", "ORCID": null, "country": null }, { "author_id": 242021, "given_name": "Concepción", "family_name": "Delgado", "ORCID": null, "country": null }, { "author_id": 253195, "given_name": "José Antonio", "family_name": "López Guerrero", "ORCID": null, "country": null }, { "author_id": 253196, "given_name": "Antonio", "family_name": "González-Pérez", "ORCID": null, "country": null }, { "author_id": 253197, "given_name": "María E", "family_name": "Sáez", "ORCID": null, "country": null }, { "author_id": 175615, "given_name": "Luisa María", "family_name": "Villar", "ORCID": "http://orcid.org/0000-0002-9067-3668", "country": null }, { "author_id": 253198, "given_name": "José Carlos", "family_name": "Álvarez-Cermeño", "ORCID": null, "country": null }, { "author_id": 243584, "given_name": "Carmen", "family_name": "Picón", "ORCID": null, "country": null }, { "author_id": 241231, "given_name": "Rafael", "family_name": "Arroyo", "ORCID": null, "country": null }, { "author_id": 253199, "given_name": "Jezabel", "family_name": "Varadé", "ORCID": null, "country": null }, { "author_id": 253200, "given_name": "Elena", "family_name": "Urcelay", "ORCID": null, "country": null }, { "author_id": 240611, "given_name": "Guillermo", "family_name": "Izquierdo", "ORCID": null, "country": null }, { "author_id": 253201, "given_name": "Miguel", "family_name": "Lucas", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "A new risk variant", "multiple sclerosis", "the immunoglobulin heavy chain locus associates", "intrathecal IgG", "IgM index", "oligoclonal bands" ], "doi": "10.1177/1352458514556302", "access": "open", "takeaways": " Recent findings have shown a correlation between the intrathecal IgG index and variants at the immunoglobulin heavy chain (IGHC) locus in patients with multiple sclerosis . We found that rs11621145 showed statistically significant evidence for association with susceptibility to MS .", "categories": [] }, { "article_id": 380602, "title": "Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Neuroretinal atrophy is associated with whole-brain atrophy and disease activity in multiple sclerosis (MS). Recent findings support that subclinical visual pathway involvement might also occur in neuromyelitis optica spectrum disorders (NMOSDs). </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> The objective of this study is to assess retinal thinning in MS and NMOSD and its association with disease activity. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> In total, 27 NMOSD and 54 propensity-score-matched MS patients underwent optical coherence tomography, visual acuity, and visual-evoked potentials at 2.4 years apart, in addition to routine clinical and magnetic resonance imaging (MRI) assessment. We excluded eyes with acute optic neuritis. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> In NMOSD, we detected peripapillary retinal nerve fiber layer (pRNFL) thinning in patients with disease activity during follow-up (−0.494 µm/year), but not in stable patients (−0.012 µm/year). Macular ganglion cell-inner plexiform layer (GCIPL) thinning occurred instead in all patients (−0.279 µm/year). Relapsing–remitting multiple sclerosis (RRMS) meeting NEDA-3 criteria had no pRNFL or GCIPL thinning during follow-up. Active-disease RRMS and progressive MS, both active and stable, displayed pRNFL (−0.724, −0.586, −0.556 µm/year, respectively) and GCIPL loss. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> In MS, neuroretinal atrophy was associated with disease activity but occurred in progressive MS even when achieving NEDA-3 criteria. In NMOSD, pRNFL thinning was associated with non-ocular relapses due to a spreading of inflammatory activity. GCIPL thinning was found in all patients, supporting a primary retinal pathology targeting AQP4-rich structures. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458519861603", "published_date": "2019-08-08T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 167248, "given_name": "Marco", "family_name": "Pisa", "ORCID": "http://orcid.org/0000-0001-9409-6864", "country": null }, { "author_id": 253214, "given_name": "Francesco", "family_name": "Ratti", "ORCID": null, "country": null }, { "author_id": 156055, "given_name": "Marco", "family_name": "Vabanesi", "ORCID": "http://orcid.org/0000-0002-8283-7079", "country": "IT" }, { "author_id": 244469, "given_name": "Marta", "family_name": "Radaelli", "ORCID": null, "country": null }, { "author_id": 244534, "given_name": "Simone", "family_name": "Guerrieri", "ORCID": null, "country": null }, { "author_id": 242435, "given_name": "Lucia", "family_name": "Moiola", "ORCID": null, "country": null }, { "author_id": 158344, "given_name": "Vittorio", "family_name": "Martinelli", "ORCID": "http://orcid.org/0000-0002-5987-5739", "country": null }, { "author_id": 149342, "given_name": "Giancarlo", "family_name": "Comi", "ORCID": "http://orcid.org/0000-0002-6989-1054", "country": null }, { "author_id": 156056, "given_name": "Letizia", "family_name": "Leocani", "ORCID": "http://orcid.org/0000-0001-9326-6753", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Subclinical neurodegeneration", "multiple sclerosis", "neuromyelitis optica spectrum disorder", "optical coherence tomography" ], "doi": "10.1177/1352458519861603", "access": "restricted", "takeaways": " Neuroretinal atrophy is associated with whole-brain atrophy and disease activity in multiple sclerosis . Recent findings support that subclinical visual pathway involvement might also occur in neuromyelitis optica spectrum disorders (NMOSDs) The objective of this study is to assess retinal thinning in MS and NMOSD and its association with disease activity .", "categories": [] } ] }